Evolution of Pulse Pressure Following Initiation of Antihypertensive Therapy in Patients With Essential Arterial Hypertension

N/ACompletedNCT02202525

Boehringer Ingelheim2,148 enrolled

Overview

The main purpose of this prospective, multicentre, french observational study is to analyse the evolution of pulse pressure (PP) and to identify its prognostic factors in hypertensive patients three months after initiation of a new hypertensive therapy. The PP is defined as the difference between systolic blood pressure (SBP) and diastolic blood pressure (DBP).

Study Type

OBSERVATIONAL

Enrollment

2,148

Conditions

Hypertension

Interventions

Micardis®DRUG

Other hypertensivesDRUG

Eligibility

Sex: ALL

Medical Language ↔ Plain English

Inclusion Criteria: * Patients with essential arterial hypertension needing a new antihypertensive therapy * A patient was included by the physician only if he/she had agreed after being informed about the study Exclusion Criteria:

Outcomes

Primary Outcomes

Changes from baseline in pulse pressure

Time frame: Up to 3 months after start of treatment

Number of patients with adverse drug reactions

Time frame: Up to 3 months after start of treatment

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.